New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
10:01 EDTLVS, WAG, NVO, GFI, BXP, NCLH, SPH, NTAP, DLR, ARE, AWI, WBC, RGLD, SJM, DCTOn the Fly: Analyst Upgrade Summary
Today’s noteworthy upgrades include: Alexandria Real Estate (ARE) upgraded to Overweight from Equal Weight at Evercore... Boston Properties (BXP) upgraded to Outperform from Sector Perform at RBC Capital... DCT Industrial (DCT) upgraded to Market Perform from Underperform at Wells Fargo... Digital Realty (DLR) upgraded to Overweight from Equal Weight at Evercore... Gold Fields (GFI) upgraded to Neutral from Sell at Citigroup... J.M. Smucker (SJM) upgraded to Outperform from Market Perform at Bernstein... Nortel NetApp (NTAP) upgraded to Buy from Hold at Brean Capital... Novo Nordisk (NVO) upgraded to Buy from Neutral at Nomura... Royal Gold (RGLD) upgraded to Buy from Neutral at UBS... Suburban Propane (SPH) upgraded to Buy from Neutral at BofA/Merrill... Walgreen (WAG) upgraded to Buy from Neutral at Mizuho... NetApp (NTAP) upgraded to Buy from Hold at Brean Capital... WABCO (WBC) upgraded to Buy from Neutral at Buckingham... Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus... Norwegian Cruise Line (NCLH) upgraded to Buy from Neutral at Nomura... Armstrong World (AWI) upgraded to Buy from Neutral at Citigroup.
News For ARE;BXP;DCT;DLR;GFI;SJM;NTAP;NVO;RGLD;SPH;WAG;WBC;NCLH;LVS;AWI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 23, 2015
07:00 EDTAWIArmstrong World to separate into two public companies
February 20, 2015
12:02 EDTNVOEmisphere says Novo Nordisk completes Phase 2 OG217SC trial
Emisphere Technologies (EMIS) highlighted positive Phase 2 data from Eligen licensee Novo Nordisk (NVO) pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Results of the study are available on Novo Nordisk's website. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.
February 19, 2015
10:24 EDTWBCWABCO to host investor day
Investor day to be held in New York on February 26 at 8 am. Webcast Link
09:08 EDTDLRDigital Realty announces new Portfolio Management division leadership
Subscribe for More Information
07:20 EDTNCLHNorwegian Cruise Line resumed with an Overweight at JPMorgan
Subscribe for More Information
07:17 EDTNCLHNorwegian Cruise Line price target raised to $55 from $51 at Susquehanna
Subscribe for More Information
February 18, 2015
09:45 EDTNTAPNetApp to participate in a conference call with Credit Suisse
Subscribe for More Information
February 17, 2015
18:36 EDTNCLHOn The Fly: After Hours Movers
Subscribe for More Information
17:06 EDTNCLHNorwegian Cruise Line sees FY15 adj EPS $2.70-$2.90, consensus $2.72
Subscribe for More Information
17:05 EDTNCLHNorwegian Cruise Line sees Q1 adj EPS 20c-24c, consensus 30c
Sees Q1 depreciation and amortization $80M-$85M and interest expense, net $55M-$60M.
17:03 EDTNCLHNorwegian Cruise Line reports Q4 adj. EPS 36c, consensus 37c
Subscribe for More Information
15:54 EDTSJMJ.M. Smucker targets long-term EPS growth of 8% plus
Targets long term organic growth 3%-4%.
15:51 EDTSJMJ.M. Smucker share repurchase activity on hold in near time
Subscribe for More Information
15:32 EDTNCLHNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Devon Energy (DVN), consensus $1.05... Vornado Realty (VNO), consensus $1.23... Analog Devices (ADI), consensus 61c... FirstEnergy (FE), consensus 75c... CF Industries (CF), consensus $5.08... Agilent Technologies (A), consensus 41c... Cimarex Energy (XEC), consensus 82c... Flowserve (FLS), consensus $1.13... Fossil (FOSL), consensus $3.07... Rackspace (RAX), consensus 19c... Norwegian Cruise Line (NCLH), consensus 37c... Jack in the Box (JACK), consensus 87c... Cloud Peak Energy (CLD), consensus 7c... La-Z-Boy (LZB), consensus 38c... KAR Auction Services (KAR), consensus 29c... Owens & Minor (OMI), consensus 50c... Valmont Industries (VMI), consensus $1.65... Realty Income (O), consensus 66c.
10:00 EDTGFIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:54 EDTWBCWABCO remains top truck idea, says RW Baird
Subscribe for More Information
08:03 EDTGFIGold Fields downgraded to Underperform from Sector Perform at Scotia Capital
Subscribe for More Information
07:22 EDTNTAPMitsubishi UFJ to hold a tour
Subscribe for More Information
07:15 EDTSJMConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information
06:48 EDTNTAPNimble Storage winning at NetApp's expense, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use